Biotech | August 25, 2021
Carbogen Amcis AG signs co-investment agreement
The co-investment of CHF 4 million will result in capacity expansion and support the market introduction of the customer's lead compound
The co-investment of CHF 4 million will result in capacity expansion and support the market introduction of the customer's lead compound
The investment will establish drug product manufacturing capacity for clinical trial and commercial supply in China and offer customers combined drug substance and drug product manufacturing services
CRISIL Ratings has revised its outlook on the long term ratings of Krishna Institute Of Medical Sciences Limited (KIMS) to 'Positive' from 'Stable' while reaffirming the ratings at 'CRISIL AA-/CRISIL A1+'
Caspian Debt has in principle committed up to Rs 35 crores to SAMRIDH’s commercial debt investment pool
The company expects a potential sales turnover of Rs.350-500 crores at 100 % capacity utilization
The approval allows it to market its products in the country
It strengthens Syngene’s portfolio as a fully integrated custom biomanufacturer with added mammalian and microbial capabilities for clinical and commercial supplies
Winlevi, the recently added anti-acne product with a new mechanism of action and broad-based use (vs Absorica), will further boost the derma portfolio and Speciality business growth
This robust performance is a testimony of the company's agility, resilience and strong execution capabilities during these difficult times
Deal signed with AOP Orphan for US commercial rights
Subscribe To Our Newsletter & Stay Updated
